Tecfidera Better at Preventing Relapses than Aubagio, Study Suggests

Tecfidera (dimethyl fumarate) is more efficient at preventing relapses, and has a lower discontinuation rate than Aubagio (teriflunomide), according to a Danish study.

The study “Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study” was published in the journal Neurology.

Aubagio (marketed by Sanofi Genzyme) and Tecfidera (marketed by Biogen) are two oral disease-modifying therapies used as first-line treatments for relapsing-remitting multiple sclerosis (RRMS).

Data from Phase 3 clinical trials supported the therapies’ approvals – Aubagio was assessed in the TEMSO (NCT00134563) and TOWER (NCT00751881) trials, and Tecfidera in the DEFINE (NCT00420212) and CONFIRM (NCT00451451) trials.

In summary, both therapies significantly reduced the annualized relapse rate (AAR) over two years, and the risk of 12-week confirmed disability worsening, compared to a placebo. Moreover, treatment decreased the number of new or enlarging active lesions, as shown by MRI.

However, head-to-head comparisons using real-world data assessing the effectiveness and safety

... read more at: https://multiplesclerosisnewstoday.com/2019/03/18/tecfiderabetter-at-preventing-relapses-than-aubagio-real-world-study-suggests/

Leave a Reply